Previous 10 |
Gemini Therapeutics (GMTX): FY net loss of $40.8M compared to $41.4M last year.Cash position of approximately $200M.Press Release For further details see: Gemini Therapeutics reports FY results
- Business combination with FS Development Corp. resulted in new public listing, strengthened management team, and cash position of approximately $200 million - Significantly advanced GEM103 clinical development; completed Phase 2a “ReGAtta” study enrollment; ini...
Gemini Therapeutics is bringing precision medicine and genomics to Dry AMD, a disease without an FDA-approved medicine. By focusing on CFH variants of Dry AMD, which represent over 6M patients in the US, the company is the first to bring a recombinant CFH into the clinic. Gemini's...
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Thera...
– Top Line Data for Phase 2a Study Expected in 1H 2021 – Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular diso...
Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos bri...
News, Short Squeeze, Breakout and More Instantly...
Gemini Therapeutics Inc. Company Name:
GMTX Stock Symbol:
NASDAQ Market:
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria PR Newswire WATERTOWN, Mass. , Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on t...
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) PR Newswire AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United States ...